ArticleIrish journal of medical science2015
Early results of the use of collagenase in the treatment of Dupuytren's contracture.
Article in Irish journal of medical science, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 12 citations in OpenAlex.
- Flexor Tendon Rupture Following CollagenaseJournal of personalized medicine · 2026Review
- Long-Term Outcomes of Collagenase Clostridium Histolyticum Injection for Palmar Dupuytren's Deformity Correction.Cureus · 2021Article
- Collagenase Clostridium Histolyticum Injection for Dupuytren Contracture: 2-Year Follow-up.Clinics in orthopedic surgery · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionIn recent years, the enzyme collagenase has been developed for the percutaneous treatment of Dupuytren's contracture, allowing management of the condition as an outpatient. We present early results on the treatment of Dupuytren's contracture using injectable collagenase.
methodsPatients awaiting Fasciectomy for Dupuytren's Contracture were selected for enrolment. Contracture cords were then marked and injected with collagenase in the outpatients department. Twenty-four hours later, patients returned for an extension procedure, performed under regional anaesthesia. Hand therapy was then commenced as for surgical release. Contracture angles were measured pre-injection and at follow-up.
resultsThirteen fingers were treated in 10 patients with a mean age of 66 years. Eight little fingers and five ring fingers were treated. Four fingers had isolated metacarpophalangeal joint (MCPJ) contracture, one finger had isolated proximal interphalangeal joint (PIPJ) contracture and the remainder had combined contractures. Mean pre-treatment MCPJ contracture was 58.6° and the mean pre-treatment PIPJ contracture was 39°. Post-treatment contracture was 4.23° and 9° for the MCPJ and PIPJ, respectively. All patients were satisfied with their results. COMPLICATIONS: Significant post-injection bruising occured in one patient. Skin tears occurred in 11 digits, and in all cases healed without intervention. No tendon rupture occurred.
conclusionsCollagenase is a safe and effective outpatient-based treatment for Dupuytren's contracture, which may be useful in controlling surgical waiting lists. We recommend its use as first-line treatment in patients who are unsuitable more invasive treatment alternatives.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.